Findings from a recent phase II/III trial, RELATIVITY-047, evaluating "dual inhibition of LAG-3 and PD-1 using a new combination of LAG-3-blocking antibody relatlimab and PD-1 blocking antibody nivolumab..." were published by the Texas MD Anderson Cancer Center in The New England Journal of Medicine. A cell surface molecule expressed on immune cells, LAG-3 "negatively regulates T-cell proliferation and effector T-cell function." The RELATIVITY-047 study evaluated relatlimib and nivolumab together as a fixed dose regimen compared to patients receiving only nivolumab alone over a 4 week period in patents with untreated metastatic or unresectable melanoma. Progression free survival was 10.1 months in patients receiving the relatlimab-nivolumab combination vs 4.6 months for those only being administered nivolumab.
To read more about this trial, click here.
Sources mentioned
- Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 2022;386:24-34. DOI: 10.1056/NEJMoa2109970
- Frampton AE, Sivakumar S. A New Combination Immunotherapy in Advanced Melanoma. N Engl J Med 2022;386:91-92. DOI: 10.1056/NEJMe2116892
No comments:
Post a Comment